The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
about
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fractionDigitalis for treatment of heart failure in patients in sinus rhythmNurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents and angiotensin receptor blockers for patients with left ventricular systolic dysfunctionMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerDigitalis for treatment of heart failure in patients in sinus rhythmStatistical Methods for Cardiovascular ResearchersPopulation pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemateExpression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted micePreservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarctionAlterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathyDebate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trialCytokines as new treatment targets in chronic heart failureChronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failureEffect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysisThird-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failureSignaling effectors underlying pathologic growth and remodeling of the heartβ-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literatureNew advances in beta-blocker therapy in heart failureThe relationship between the MMP system, adrenoceptors and phosphoprotein phosphatasesPeripartum cardiomyopathyCardiac innervation and sudden cardiac death.A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart FailureVarying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelinesDrug therapy for heart failure in older patients-what do they want?Non-compliance and knowledge of prescribed medication in elderly patients with heart failureAdverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Treatment of the elderly post-myocardial infarction patientPatterns of pharmacotherapy in patients hospitalised for congestive heart failureGetting it right: being smarter about clinical trialsThe human sympathetic nervous system: its relevance in hypertension and heart failureBisoprolol for congestive heart failureAnti-NO action of carvedilol in cell-free system and in vascular endothelial cellsNebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardiumPharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failureJust the berries. Management of heart failureRenoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expressionCharacterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium
P2860
Q24187047-64477EED-62A2-47DB-873B-7366C586DEE7Q24194992-E6E5F11A-CE55-47FF-A484-4B6124FF57DAQ24202952-7380E304-BF4F-47DA-A1D4-4803C014860BQ24234511-E0F401AB-D8E5-4012-868C-97FF452210E8Q24241097-E07854D4-BB92-48D9-BC6A-120CF8D2723BQ24247158-2E750566-19F1-4108-A3F6-779B29289423Q24289000-9F1ED4FD-341D-4E12-B5EA-D0E19ED30990Q24647717-0FDB1B23-8DDC-4A7C-8701-C518CD011B3DQ24650383-E7C45592-02CE-414D-BA59-E3EFA647EE22Q24656335-C09D94A3-4CA7-46B3-82D5-28FFED14CE48Q24680224-75E18570-6520-4E7E-A1AD-6915F1B6A83CQ24792660-709B7F3F-B53B-4EA6-8969-5B043CD5EE35Q24792670-3FAE1B3C-7D3D-41B6-842E-8F796443B943Q24793341-6FAA45C0-97A4-4808-86E0-AE9131BC19BCQ24799394-5EA233A7-0234-4F7C-B6C6-58CADD6D474FQ24804131-F5CB3C84-1A64-4DC7-B852-BF17C975008FQ26751460-C73CD2F7-1358-4625-8E84-DA5BD52A0975Q26822825-A82BE849-D1E2-4E78-9555-4F68D775FD53Q26825154-6CD87A0A-007F-4CB5-BB30-76EA145D5787Q26861630-AD09B327-FB83-4D4A-AE65-39F53DD0E9ECQ26865919-41BADC7D-1ADF-4974-8140-F5FDD487F09FQ27003263-070E2AAA-3BE8-4646-BA17-CAB65523CACCQ27015972-343BDC11-E82C-4C58-93DD-43DE5E68268CQ27339391-B66AC3EE-DDC1-4F6B-886E-CABCB19D98D1Q28068618-BA02A9F2-A2AF-4894-BCF5-08257D3E47E5Q28069387-88848575-31F4-4C3F-9E86-6E8AB91C34AEQ28083086-0C7B18D3-1DAC-41B2-805A-F283AB09CB02Q28143264-D1A571C8-81A0-47B0-9431-00305F4343A0Q28182735-DFF8BF76-239B-48AB-A3FD-12D4811D775BQ28191018-C916C11C-B2E4-4DD9-906D-86E459C0BD51Q28195422-D2BF9618-EAAA-45FF-8656-34A71DFE0E9CQ28196471-F8ECBF05-245D-4F6D-ADFA-E93F7AA4DDA2Q28264609-C5BD95A2-D450-4B6E-A674-6EBD47BF027BQ28264977-7A174476-BEA7-4172-A431-306E80FB8B1DQ28344089-62B04485-897B-49E5-9C7A-DB67C8E75AD2Q28345779-98C25EB4-0A51-4D91-8606-B769B76F75FCQ28346899-6B9F3D8C-0138-4744-A49A-2B197E1D1269Q28361657-374552AB-FCB4-4D1B-884F-12AD0C254CF2Q28362709-6DED3E00-7E75-4C84-BEED-3A389E8E7BB9Q28363078-87831DEA-1722-4313-B6FB-AD6112C8A93A
P2860
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@en
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@nl
type
label
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@en
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@nl
prefLabel
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@en
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@nl
P2093
P1476
The effect of carvedilol on mo ...... lol Heart Failure Study Group.
@en
P2093
E M Gilbert
M B Fowler
M R Bristow
N H Shusterman
W S Colucci
P304
P356
10.1056/NEJM199605233342101
P407
P577
1996-05-01T00:00:00Z